<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1654">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319810</url>
  </required_header>
  <id_info>
    <org_study_id>SIMR_Kile_IVIG POC</org_study_id>
    <nct_id>NCT03319810</nct_id>
  </id_info>
  <brief_title>Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease</brief_title>
  <official_title>Proof of Concept of the Effect of Intravenous Immunoglobulin on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutter Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutter Health</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept study to determine if changes in brain amyloid levels are evident&#xD;
      three months after infusion of 0.4 g/kg of IVIG every 14 days x 5 infusions. Amyloid levels&#xD;
      will be measured by Florbetapir PET and retinal scan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      This is a single center, open label, proof of concept, out-patient study. Subjects will&#xD;
      undergo Florbetapir PET and have retinal amyloid levels measured, receive an infusion of IVIG&#xD;
      at 0.4 g/kg every 14 days for a total of five infusions, and repeat PET and retinal amyloid&#xD;
      measures three months after the first infusion.&#xD;
&#xD;
      Subject population:&#xD;
&#xD;
      The study population will consist of male and female subjects diagnosed with mild cognitive&#xD;
      impairment (MCI) due to Alzheimer disease (AD).&#xD;
&#xD;
      Estimated study duration:&#xD;
&#xD;
      The duration of each study subject is approximately 4 months, including one screening visit&#xD;
      over a period of approximately 28 days, 5 days of infusions over a 2-month period of time,&#xD;
      and a follow-up visit at 3 months after the first infusion.&#xD;
&#xD;
      Description of study drug:&#xD;
&#xD;
      Octagam is an FDA approved 10% human normal immunoglobulin solution ready for intravenous&#xD;
      administration.&#xD;
&#xD;
      Study drug dosage:&#xD;
&#xD;
      The dose level of IVIG at 0.4 g/kg will be administered by IV infusion once every 14 days for&#xD;
      two months.&#xD;
&#xD;
      Concomitant therapy:&#xD;
&#xD;
      Concomitant medications will be assessed at all study visits. Concomitant medications are&#xD;
      prescribed or over-the-counter medications and should be consistent with the&#xD;
      inclusion/exclusion criteria. Concomitant medication appropriate to the subject's condition&#xD;
      may be prescribed during the course of the study with the exception of those listed above.&#xD;
&#xD;
      Routine vaccinations (i.e., flu vaccination) with commercially available therapeutics are&#xD;
      permitted but must not be given within four weeks before or after the administration of the&#xD;
      study drug.&#xD;
&#xD;
      Evaluations by visit:&#xD;
&#xD;
      Screening procedures at visit 1 will take place up to 28 days prior to Visit 2 (Day 1)&#xD;
      dosing. Screening labs and assessments will be performed during the screening period. The&#xD;
      first dose of study drug is administered on Day 1. Visits 2 through 6 have a ±1 day window&#xD;
      and occur every 14 days over two months. The investigator will determine if a subject is&#xD;
      suitable to continue following a missed infusion. Visit 7 has a ±7 day window.&#xD;
&#xD;
      All study screening data from Visit 1 including laboratory results must be reviewed for study&#xD;
      eligibility prior to receiving first dose of study drug. Prior to infusion, a review of&#xD;
      concomitant medications and AEs takes place. If the subject continues to be eligible for&#xD;
      enrollment, the subject will be infused with study medication and will remain in the infusion&#xD;
      clinic for at least 1 hour following the infusion for safety assessments on Visit 2 (Day 1),&#xD;
      and 15 minutes for the subsequent visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2018</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single center, open label, proof of concept, out-patient study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Amyloid deposition in the brain is thought to lead to the development of cognitive decline and conversion to AD. Each participant's amyloid burden can also be quantified through the computation of a Standard Uptake Value ratio (SUVr).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Baseline Retinal Amyloid Imaging (RAI) at 3 Months</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>This is a noninvasive imaging technique that can detect amyloid-beta deposition in the retinas of the eye.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>infusion of IVIG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octagam 10%</intervention_name>
    <description>FDA approved human normal immunoglobulin solution ready for intravenous administration</description>
    <arm_group_label>infusion of IVIG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 50 to &lt;85 years.&#xD;
&#xD;
          2. Evidence of amyloid pathology on Florbetapir PET at screening.&#xD;
&#xD;
          3. Diagnosis of MCI due to AD based on NIA-AA criteria. (APPENDIX A)&#xD;
&#xD;
          4. MRI brain (with past 24 months) which shows evidence of mild hippocampal atrophy&#xD;
             and/or bilateral parietal atrophy.&#xD;
&#xD;
          5. CDR score of 0.5&#xD;
&#xD;
          6. Mini-Mental State Examination (MMSE) score of 24-30, inclusive.&#xD;
&#xD;
          7. Rosen Modified Hachinski Ischemic score ≤4.&#xD;
&#xD;
          8. Receiving stable doses of medication(s) for the treatment of non-excluded medical&#xD;
             condition(s) for at least 30 days prior to screening. Cholinesterase inhibitors and&#xD;
             memantine are allowed if doses have stable been least 30 days prior to screening.&#xD;
&#xD;
          9. Agree to refrain from participating in any treatment or clinical trial targeting&#xD;
             amyloid for the duration of the study.&#xD;
&#xD;
         10. Agree to refrain from taking any herbal supplement considered to enhance cognition&#xD;
             unless approved by the investigator for the duration of the study.&#xD;
&#xD;
         11. Ability to attend all clinical visits and have an informant capable of accompanying&#xD;
             the subject on specific clinic visits.&#xD;
&#xD;
         12. The subject's collaborative informant (support person) must be someone who has known&#xD;
             the subject for at least 4 years and has had approximately 2 or more separate&#xD;
             communications with the study participant per month (at least one of these&#xD;
             communications in person).&#xD;
&#xD;
         13. Fluency in English and evidence of adequate premorbid intellectual functioning.&#xD;
&#xD;
         14. Adequate manual dexterity, visual, and auditory abilities to perform all aspects of&#xD;
             the cognitive and functional assessments.&#xD;
&#xD;
         15. Venous access suitable for repeated infusions and phlebotomy.&#xD;
&#xD;
         16. In the opinion of the investigator, the subject and informant will be compliant and&#xD;
             have a high probability of completing the study, including all scheduled evaluations&#xD;
             and required tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has significant neurological disease other than MCI that in the opinion of the&#xD;
             investigator may affect cognition.&#xD;
&#xD;
          2. History of clinically evident stroke or history of clinically significant carotid or&#xD;
             vertebrobasilar stenosis or plaque.&#xD;
&#xD;
          3. History of seizures, excluding febrile seizures in childhood.&#xD;
&#xD;
          4. History of screening visit brain MRI scan indicative of any other significant&#xD;
             abnormality, including but not limited to multiple microhemorrhages (2 or more),&#xD;
             history or evidence of a single prior hemorrhage &gt; 1 cm3, multiple lacunar infarcts (2&#xD;
             or more) or evidence of a single prior infarct &gt; 1 cm3, evidence of a cerebral&#xD;
             contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or&#xD;
             space occupying lesions of significance as determined by the PI (e.g., arachnoid cysts&#xD;
             or brain tumors such as meningioma).&#xD;
&#xD;
          5. Brain MRI shows moderate or severe cortical or hippocampal atrophy.&#xD;
&#xD;
          6. Sensitivity to Florbetapir.&#xD;
&#xD;
          7. Other present/planned ionized radiation that, in combination with planned exposure to&#xD;
             PET ligands for this study, would result in cumulative exposure that would exceed&#xD;
             recommended limits.&#xD;
&#xD;
          8. Ophthalmologic condition that would interfere with retinal amyloid imaging.&#xD;
&#xD;
          9. Current presence of a clinically significant major psychiatric disorder (e.g., Major&#xD;
             Depressive Disorder) according to the criteria of the Diagnostic and Statistical&#xD;
             Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) or symptom (e.g.,&#xD;
             hallucinations) that in the opinion of the investigator could affect the subject's&#xD;
             ability to complete the study.&#xD;
&#xD;
         10. Current clinically significant systemic illness that is likely to result in&#xD;
             deterioration of the subject's condition or affect the subject's safety during the&#xD;
             study including but not limited to renal failure or myocardial infarction.&#xD;
&#xD;
         11. History of cancer within the last 5 years, with the exception of nonmetastatic basal&#xD;
             cell carcinoma, and squamous cell carcinoma of the skin.&#xD;
&#xD;
         12. Uncontrolled hypertension (diastolic BP&gt; 100 mmHg or systolic BP&gt; 160 mmHg, sitting).&#xD;
&#xD;
         13. History or evidence of any clinically significant autoimmune disease or disorder of&#xD;
             the immune system (e.g., Crohn's Disease, Rheumatoid Arthritis)&#xD;
&#xD;
         14. Clinically significant infection within the last 30 days (e.g., chronic persistent or&#xD;
             acute infection (eg, upper respiratory infection [URI], urinary tract infection&#xD;
             [UTI]).&#xD;
&#xD;
         15. Female subjects of childbearing potential.&#xD;
&#xD;
         16. Other clinically significant abnormality on physical, neurological, laboratory, vital&#xD;
             signs or ECG examination (e.g., atrial fibrillation) that could compromise the study&#xD;
             or be detrimental to the subject.&#xD;
&#xD;
         17. Weight greater than 120 kg (264 lbs).&#xD;
&#xD;
         18. Excessive smoking defined as more than 20 cigarettes per day.&#xD;
&#xD;
         19. History of alcohol or drug dependence or abuse as defined by DSM-IV criteria within&#xD;
             the last 2 years.&#xD;
&#xD;
         20. Severe liver or kidney disease verified by the PI review of ALT, AST and creatinine.&#xD;
&#xD;
         21. Known coagulopathy, thrombosis, or low platelet count.&#xD;
&#xD;
         22. Hemoglobin less than 11 g/dL.&#xD;
&#xD;
         23. Known deficiency to IgA.&#xD;
&#xD;
         24. Positive serology for Hepatitis B or C, or HIV.&#xD;
&#xD;
         25. History of anti-amyloid treatment, immunotherapy, or other experimental treatment for&#xD;
             MCI or Alzheimer disease.&#xD;
&#xD;
         26. Concurrent use of anticholinergic drugs including diphenhydramine.&#xD;
&#xD;
         27. Current use of anticoagulant medications (except the use of aspirin 325 mg/day or&#xD;
             less, plavix, aggrenox, and persantine but not for stroke).&#xD;
&#xD;
         28. Concurrent use of opioid pain relievers and related synthetic derivatives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn Kile, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutter Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carol Parise, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sutter Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sutter Neuroscience Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):106-112. doi: 10.1136/jnnp-2015-311486. Epub 2015 Sep 29.</citation>
    <PMID>26420886</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <results_first_submitted>March 22, 2019</results_first_submitted>
  <results_first_submitted_qc>March 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sutter Health</investigator_affiliation>
    <investigator_full_name>Shawn Kile, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>MCI, Alzheimer Disease, AD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03319810/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infusion of IVIG</title>
          <description>Octagam 10%: FDA approved human normal immunoglobulin solution ready for intravenous administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infusion of IVIG</title>
          <description>Octagam 10%: FDA approved human normal immunoglobulin solution ready for intravenous administration</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.30" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Standard Uptake Value Ratio (SUVr)</title>
          <description>SUVr is the ratio of activity per unit volume of a region of interest to the activity per unit whole body volume.</description>
          <units>standard uptake value ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.57" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months</title>
        <description>Amyloid deposition in the brain is thought to lead to the development of cognitive decline and conversion to AD. Each participant's amyloid burden can also be quantified through the computation of a Standard Uptake Value ratio (SUVr).</description>
        <time_frame>Baseline to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of IVIG</title>
            <description>Octagam 10%: FDA approved human normal immunoglobulin solution ready for intravenous administration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months</title>
          <description>Amyloid deposition in the brain is thought to lead to the development of cognitive decline and conversion to AD. Each participant's amyloid burden can also be quantified through the computation of a Standard Uptake Value ratio (SUVr).</description>
          <units>standard uptake value ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.83" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Baseline Retinal Amyloid Imaging (RAI) at 3 Months</title>
        <description>This is a noninvasive imaging technique that can detect amyloid-beta deposition in the retinas of the eye.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of IVIG</title>
            <description>Octagam 10%: FDA approved human normal immunoglobulin solution ready for intravenous administration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Retinal Amyloid Imaging (RAI) at 3 Months</title>
          <description>This is a noninvasive imaging technique that can detect amyloid-beta deposition in the retinas of the eye.</description>
          <units>autofluorescent spot count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.00" spread="68.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.75" spread="46.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infusion of IVIG</title>
          <description>Octagam 10%: FDA approved human normal immunoglobulin solution ready for intravenous administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carol Parise, PhD, Research Scientist</name_or_title>
      <organization>Sutter Institute for Medical Research</organization>
      <phone>(916) 887-4744</phone>
      <email>PariseC@sutterhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

